---
category: news
title: "Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC"
excerpt: "OnKai's AI models redefine the methodologies and economics of clinical trials TEL AVIV, Israel, July 10, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) (\"Galmed\" or the \"Company\"), a"
publishedDateTime: 2023-07-10T12:00:00Z
originalUrl: "https://www.benzinga.com/pressreleases/23/07/n33164058/galmed-to-employ-onkais-disruptive-artificial-intelligence-ai-in-its-planned-phase-2a-clinical-tri"
webUrl: "https://www.benzinga.com/pressreleases/23/07/n33164058/galmed-to-employ-onkais-disruptive-artificial-intelligence-ai-in-its-planned-phase-2a-clinical-tri"
ampWebUrl: "https://www.benzinga.com/amp/content/33164058"
cdnAmpWebUrl: "https://www-benzinga-com.cdn.ampproject.org/c/s/www.benzinga.com/amp/content/33164058"
type: article

provider:
  name: Benzinga.com
  domain: benzinga.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://www.benzinga.com/next-assets/images/schema-image-default.png"
    width: 1043
    height: 1043
    isCached: true

secured: "9r/D8dI+xty5LXhqij6E3XttJE2Pn21Gd2TFoIPbeWjhsajqM+tT8apidBcfL6vUBv57azGfQZn2PSo2zpq+5s+tuBCMlVbVVfXZmwXzIQKcedPlVe1iSBollpcTr4/CyQXEAhULrw+tR2AzQ6qaaMPElNfRfuJtU0DxfCfT1OGAm8gS8CfBpY0NNyfFFG9auXRlNkJxwePQikvgRxhuvuALGhSAzin2vpO1FmtNDIiXYfKr8h8VuzCQcfFqiPMNEhw7dlh1EUPLcoVPLO3bRUhpTVG4SKJ6kL7ZJBLm9wBWGfsiBRzeu+Y0XHiWA0llXeCz8yaPzZ+1dvkrAxfVh/OcfBrU8SDKrXvPI/U4LXI=;I2UcjMxby/u3DOlWga+6Qg=="
---

